Integrated Biopharma, Inc. INBP
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 43.87M | 48.25M | 52.09M | 53.43M | 54.35M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 43.87M | 48.25M | 52.09M | 53.43M | 54.35M |
| Cost of Revenue | 43.07M | 46.01M | 48.02M | 48.22M | 48.79M |
| Gross Profit | 800.00K | 2.24M | 4.07M | 5.21M | 5.56M |
| SG&A Expenses | 3.51M | 3.49M | 3.49M | 3.52M | 3.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 46.58M | 49.50M | 51.51M | 51.73M | 52.33M |
| Operating Income | -2.71M | -1.25M | 577.00K | 1.69M | 2.02M |
| Income Before Tax | -2.56M | -1.12M | 695.00K | 1.75M | 2.06M |
| Income Tax Expenses | 279.00K | 536.00K | 901.00K | 1.08M | 1.25M |
| Earnings from Continuing Operations | -2.84 | -1.65 | -0.21 | 0.67 | 0.81 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.84M | -1.65M | -206.00K | 672.00K | 808.00K |
| EBIT | -2.71M | -1.25M | 577.00K | 1.69M | 2.02M |
| EBITDA | -2.41M | -953.00K | 882.00K | 2.00M | 2.34M |
| EPS Basic | -0.09 | -0.05 | -0.01 | 0.02 | 0.03 |
| Normalized Basic EPS | -0.05 | -0.02 | 0.01 | 0.04 | 0.04 |
| EPS Diluted | -0.10 | -0.06 | -0.01 | 0.02 | 0.03 |
| Normalized Diluted EPS | -0.05 | -0.02 | 0.01 | 0.04 | 0.04 |
| Average Basic Shares Outstanding | 124.24M | 123.79M | 123.03M | 122.15M | 121.19M |
| Average Diluted Shares Outstanding | 124.60M | 124.15M | 124.61M | 124.85M | 124.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |